2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Adverse Events, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

3394 Alternating maintenance therapy with venetoclax, azacitidine, and an immunomodulatory regimen in patients with acute myeloid leukemia not undergoing transplantation: Efficacy and safety

Lin Chen, MD, Ruihua Mi, MD, PhD2, Lin Wang, MD3, Yixuan MA, PhD4, Cheng CHENG5, Genjie Wang, N/A6, Haitao WANG7, Xiaolin HAN8, Xudong Wei9
1 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
2 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
3 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
4 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
5 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
6 Shangqiu First People’s Hospital, Shangqiu, China
7 Kaifeng 155 Hospital, Kaifeng, China
8 The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China
9 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China

Background and Objectives:

Maintenance options remain limited for patients with acute myeloid leukemia (AML) who achieve measurable residual disease (MRD)-negative remission but do not undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT). We evaluated the efficacy and safety of an alternating maintenance strategy consisting of an immunomodulatory regimen, venetoclax, and azacitidine in this patient population.

Methods:

This multicenter, prospective, single-arm, exploratory phase II study enrolled adult patients with AML who achieved complete remission or complete remission with incomplete hematologic recovery (CR/CRi) and MRD negativity after prior treatment and did not undergo allo-HSCT (ClinicalTrials.gov identifier: NCT06256627). Maintenance was administered in repeating 3-month cycles. During month 1, patients received an immunomodulatory regimen consisting of interferon-α-1b at 60 μg subcutaneously every other day, interleukin-2 at 1 million IU subcutaneously every other day, and thalidomide at 100 mg orally every night. Venetoclax was administered during month 2, followed by azacitidine during month 3. The 3-month cycle was repeated for a planned treatment duration of 24 months. Molecular relapse-free survival (mRFS) was defined as the time from initiation of maintenance therapy to MRD conversion to positivity or death from any cause, whichever occurred first. Overall survival (OS) was defined as the time from initiation of maintenance therapy to death. OS and mRFS were estimated using the Kaplan–Meier method, and median follow-up was estimated using the reverse Kaplan–Meier method. The data cutoff date was July 15, 2026.

Results:

Twenty-seven patients were enrolled. The median age was 62 years (range, 33–79 years), and 16 patients (59.3%) were female. By 2022 European LeukemiaNet risk classification, 13 patients (48.1%) had favorable-, 9 (33.3%) had intermediate-, and 5 (18.5%) had adverse-risk disease. In addition, 9 patients (33.3%) were categorized as having study-defined high-risk disease, defined as either ELN 2022 adverse-risk disease or the co-occurrence of DNMT3A, FLT3, and NPM1 mutations.

At cutoff, 13 patients (48.1%) had completed the planned 24 months of maintenance, 12 (44.4%) remained on treatment, and 2 (7.4%) had discontinued early because of molecular relapse. Three molecular relapses occurred: two before completion of the planned 24-month maintenance period and one after completion of maintenance therapy. One patient died following relapse. All three mRFS events occurred in patients with RUNX1 mutations. Because of the limited sample size, no formal comparison of prognostic outcomes according to mutation status was performed.

The median follow-up estimated using the reverse Kaplan–Meier method was 38.5 months (95% confidence interval [CI], 12.8–47.8 months). In the overall cohort, the 24-month OS rate was 94.4% (95% CI, 66.6%–99.2%), and the 24-month mRFS rate was 90.1% (95% CI, 64.9%–97.5%). Median OS and median mRFS were not reached.

Among patients with ELN 2022 intermediate- or adverse-risk disease, the 24-month OS rate was 88.9% (95% CI, 43.3%–98.4%), and the 24-month mRFS rate was 81.2% (95% CI, 41.5%–95.2%). In the study-defined high-risk subgroup, the 24-month OS rate was 83.3% (95% CI, 27.3%–97.5%), and the 24-month mRFS rate was 71.1% (95% CI, 23.3%–92.3%).

The most common adverse events were hematologic toxicities. Grade 3 or 4 neutropenia and thrombocytopenia each occurred in 48.1% of patients but were manageable with dose reductions. During the immunomodulatory treatment phase, fever, chills, and myalgia occurred in 100%, 77.8%, and 29.6% of patients, respectively. These symptoms generally occurred during the first few doses and gradually diminished with subsequent administration. Gastrointestinal adverse events occurred in 85.2% of patients and included decreased appetite, nausea, and constipation. These events were managed primarily with supportive care, and only three patients required antiemetic treatment. No invasive infections, major bleeding events, treatment-related deaths, permanent treatment discontinuations due to toxicity.

Conclusions:

In patients with AML who achieved MRD-negative remission and did not undergo allo-HSCT, alternating maintenance therapy with an immunomodulatory regimen, venetoclax, and azacitidine showed the potential to maintain deep remission and provide durable survival, with a manageable safety profile.

Lin Chen, MD: No relevant conflicts of interest to declare.